H.A.J.PHARMACEUTICALS LIMITED

Company Registration Number:
15375893 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2024

Period of accounts

Start date: 29 December 2023

End date: 31 December 2024

H.A.J.PHARMACEUTICALS LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2024

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8
Balance sheet notes - 11

H.A.J.PHARMACEUTICALS LIMITED

Company Information

for the Period Ended 31 December 2024




Director: Hassan Ali
Ayesha Javed
Registered office: 72
Duckworth Terrace
Bradford
GBR
BD9 5HH
Company Registration Number: 15375893 (England and Wales)

H.A.J.PHARMACEUTICALS LIMITED

Directors' Report Period Ended 31 December 2024

The directors present their report with the financial statements of the company for the period ended 31 December 2024

Principal Activities

The company principal activity was providing cover staff for Pharmacies

Directors

The directors shown below have held office during the whole of the period from 29 December 2023 to 31 December 2024
Hassan Ali
Ayesha Javed

This report was approved by the board of directors on 29 September 2025
And Signed On Behalf Of The Board By:

Name: Hassan Ali
Status: Director

H.A.J.PHARMACEUTICALS LIMITED

Profit and Loss Account

for the Period Ended 31 December 2024


Notes

2024
£
Gross turnover (not including turnover from inside OPW engagements) 0
Gross turnover from inside OPW engagements 65,665
Deductions from gross turnover from inside OPW engagements ( 0 )
Cost of sales ( 0 )
Gross Profit or (Loss) 65,665
Income from coronavirus (COVID-19) business support grants 0
Distribution Costs ( 0 )
Administrative Expenses ( 51,196 )
Other operating income 0
Operating Profit or (Loss) 14,469
Interest Receivable and Similar Income 0
Interest Payable and Similar Charges ( 0 )
Profit or (Loss) Before Tax 14,469
Tax on Profit ( 2,749 )
Profit or (Loss) for Period 11,720

The notes form part of these financial statements

H.A.J.PHARMACEUTICALS LIMITED

Balance sheet

As at 31 December 2024


Notes

2024
£
Fixed assets
Tangible assets: 4 1,650
Total fixed assets: 1,650
Current assets
Cash at bank and in hand: 1
Total current assets: 1
Net current assets (liabilities): 1
Total assets less current liabilities: 1,651
Total net assets (liabilities): 1,651

The notes form part of these financial statements

H.A.J.PHARMACEUTICALS LIMITED

Balance sheet continued

As at 31 December 2024


Notes

2024
£
Capital and reserves
Called up share capital: 1
Revaluation reserve: 5 1,650
Shareholders funds: 1,651

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 29 September 2025
And Signed On Behalf Of The Board By:

Name: Hassan Ali
Status: Director

The notes form part of these financial statements

H.A.J.PHARMACEUTICALS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

H.A.J.PHARMACEUTICALS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 2. Employees


    2024
    Average number of employees during the period 3

H.A.J.PHARMACEUTICALS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 3. Off balance sheet disclosure

    No

H.A.J.PHARMACEUTICALS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Tangible assets

Office equipment Total
Cost £ £
Additions 5,316 5,316
Disposals - -
Revaluations - -
Transfers - -
At 31 December 2024 5,316 5,316
Depreciation
Charge for year 3,666 3,666
On disposals - -
Other adjustments - -
At 31 December 2024 3,666 3,666
Net book value
At 31 December 2024 1,650 1,650

H.A.J.PHARMACEUTICALS LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

5. Revaluation reserve


2024
£
Surplus or deficit after revaluation 1,650
Balance at 31 December 2024 1,650

This is the capital introduced to buy assets.